Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.1400 (7.08%) ($5.1400 - $5.1400) on Thu. Apr. 1, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.03% (three month average) | RSI | 55 | Latest Price | $5.1400(7.08%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.2% a day on average for past five trading days. | Weekly Trend | ADMS declines -4.2% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) BWX(39%) EMHY(33%) TIP(28%) JNK(25%) IGOV(22%) | Factors Impacting ADMS price | ADMS will decline at least -2.515% in a week (0% probabilities). TLT(-22%) TAN(-14%) VXX(-12%) UUP(-39%) INDA(-17%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.515% (StdDev 5.03%) | Hourly BBV | 0.4 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $4.94(4.05%) | 10 Day Moving Average | $5.11(0.59%) | 20 Day Moving Average | $5.13(0.19%) | To recent high | -22.8% | To recent low | 2.4% | Market Cap | $145m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |